Md. biotech sees good results from respiratory virus vaccine trial

Novavax Inc., a Gaithersburg-based biotechnology company, on Tuesday announced that it had seen positive data from its phase 2 trial of its respiratory syncytial virus F-protein nanoparticle vaccine candidate. There is no approved vaccine for the virus, which is the most common cause of lower respiratory tract infections and the leading viral cause of severe lower respiratory tract ...

To purchase a reprint of this article, contact reprints@thedailyrecord.com.